TICKERNERD
Menu
AVXLAVXLHealthcare · Biotechnology

AVXL Stock Forecast: Anavex Life Sciences Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.62
−1.50% on the day

The 1 Wall Street analysts covering Anavex Life Sciences Corp. hold a median 12-month price target of $20 — +663.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$242.9M
Ticker Nerd rank
25 / 100
Median analyst target
$20
Analysts covering
1
Revenue$0.0
Operating income$6.8M
Net income$7.8M
Free cash flow−$9.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.1%
1M
−25.4%
YTD
−26.4%
1Y
−72.7%
From 52W high
−73.7%
From 52W low
+12.0%
$2.34
$9.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVXL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anavex Life Sciences Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
80
Quality
68
Size
65
Issuance
43
Value
37
Revisions
25
Volatility
25
Accruals
15
Momentum
8

Growth (80): Sales and profits are climbing, and climbing faster than before.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVXL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVXL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26AVXLHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +663.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Mar 2026D. Boral CapitalMaintainsBuy$24
26 Mar 2026D. Boral CapitalMaintainsBuy$24
23 Mar 2026D. Boral CapitalMaintainsBuy—
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Feb 2026D. Boral CapitalMaintainsBuy—
6 Jan 2026D. Boral CapitalMaintainsBuy—
19 Dec 2025D. Boral CapitalMaintainsBuy—
19 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Dec 2025D. Boral CapitalMaintainsBuy—
28 Nov 2025HC Wainwright & Co.ReiteratesBuy—
26 Nov 2025D. Boral CapitalMaintainsBuy—
19 Nov 2025HC Wainwright & Co.MaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
29 Oct 2025D. Boral CapitalMaintainsBuy—
24 Oct 2025Jones TradingDowngradeHold—
7 Oct 2025HC Wainwright & Co.ReiteratesBuy—
2 Oct 2025D. Boral CapitalMaintainsBuy—
1 Oct 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025D. Boral CapitalMaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVXL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AVXL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Anavex Life Sciences Corp. returned −72.7% against +17.5% for the S&P 500, dividends included.

AVXL vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26AVXLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVXL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Anavex Life Sciences Corp. (AVXL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.9×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 43% of US stocks

EV / EBITDA
−2.7×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−12.8%

Higher than 34% of US stocks

Return on assets
−9.7%

Higher than 27% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Anavex Life Sciences Corp. (AVXL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anavex Life Sciences Corp. has a market value of $242.9M and an enterprise value of $124.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$13.0M.

  • Diluted earnings per share, trailing twelve months: $−0.15.

  • Free cash flow in the twelve months to 30 June 2026: −$29.3M.

  • Shares outstanding: 92.7M.

  • Trailing P/E: −4.9×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Anavex Life Sciences Corp. employs 34 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AVXL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVXLAnavex Life Sciences Corp.$242.9M
25
VRXAVERAXA Biotech AG$243.8M
20
RNACCartesian Therapeutics, Inc.$240.0M
24
LCTXLineage Cell Therapeutics, Inc.$251.6M
55
WHWKWhitehawk Therapeutics, Inc.$234.3M
71
ALECAlector, Inc.$233.6M
41
CGENCompugen Ltd.$233.5M
81

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anavex Life Sciences Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVXL news & analysis

PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign

GlobeNewsWire · 10 Sept 2026neutral

PVG Asset Management Corp., a stockholder of Anavex Life Sciences, announced it will host an investor conference call to discuss its campaign for change in the Anavex Board of Directors ahead of the upcoming 2026 Annual Meeting of Stockholders.

Why it matters — This signals an active shareholder campaign targeting Board changes at Anavex's 2026 annual meeting, which AVXL watchers will want to follow closely.

Anavex Life Sciences Corp. (AVXL) Discusses Clinical Development Strategy and Path Forward for CNS Indications Prepared Remarks Transcript

Seeking Alpha · 9 Sept 2026neutral

Anavex Life Sciences Corp. published a prepared remarks transcript in which it discussed its clinical development strategy and path forward for its central nervous system (CNS) indications. The document outlines the company's approach to developing treatments for CNS conditions.

Why it matters — AVXL watchers would care because the transcript provides direct insight into the company's stated clinical development plans and strategic direction for its CNS-focused pipeline.

PVG Asset Management Issues Important Information About Anavex Life Sciences (AVXL)

GlobeNewsWire · 9 Sept 2026negative

PVG Asset Management Corp., a stockholder of Anavex Life Sciences, issued a statement asserting that the company's Board of Directors should be replaced and that an experienced CEO should be hired. The announcement was made via GlobeNewswire on September 9, 2026.

Why it matters — Anavex watchers would care because a major stockholder is publicly calling for leadership changes at the company's board and executive level.

Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET

GlobeNewsWire · 8 Sept 2026neutral

Anavex Life Sciences announced it will host a conference call at 4:00 PM ET on Wednesday, September 9, 2026. Interim CEO Terrie Kellmeyer, Ph.D., will discuss the Company's clinical development strategy and priorities during the call.

Why it matters — Anavex watchers would care because the call offers insight into the Company's clinical development strategy and priorities from its Interim CEO.

Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

GlobeNewsWire · 2 Sept 2026positive

Anavex Life Sciences announced it received confirmation from Nasdaq that the company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to file all required periodic reports with the SEC.

Why it matters — Regaining compliance with Nasdaq's periodic filing requirement removes a potential listing concern for AVXL and signals that the company's required SEC filings are now current.

FAQ

Frequently asked questions about AVXL stock

What is the AVXL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Anavex Life Sciences Corp. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVXL stock a buy right now?

Of the 1 analysts covering Anavex Life Sciences Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anavex Life Sciences Corp. 25 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVXL?

As at 12 Sept 2026, Anavex Life Sciences Corp. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (80 of 100).

Will AVXL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +663.4% from the last close, and Ticker Nerd's factor model ranks Anavex Life Sciences Corp. 25 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVXL stock forecast for 2030?

No analyst covering Anavex Life Sciences Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has AVXL stock performed over the past year?

Anavex Life Sciences Corp. returned -72.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anavex Life Sciences Corp. do?

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders.

What is the latest news on AVXL?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign". PVG Asset Management Corp., a stockholder of Anavex Life Sciences, announced it will host an investor conference call to discuss its campaign for change in the Anavex Board of Directors ahead of the upcoming 2026 Annual Meeting of Stockholders.

Company

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing oral therapies for central nervous system disorders. Its current pipeline targets conditions such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other neurodegenerative, neurodevelopmental, and neuropsychiatric diseases. The company’s work centers on precision medicine approaches designed to address high unmet medical needs in brain health, with a primary emphasis on advancing candidate medicines through clinical development. Anavex Life Sciences Corp. operates in the biotechnology sector and serves as a research-driven participant in the global pharmaceutical market, where it contributes to the development of potential treatments for complex neurological diseases.

CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D. · 34 employees · United States · https://www.anavex.com